分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

A scorpion venom peptide Ev37 restricts viral late entry by alkalizing acidic organelles

Fangfang Li, Yange Lang, Zhenglin Ji, Zhiqiang Xia, Yuewen Han, Yuting Cheng, Gaomin Liu, Fang Sun, Yonghui Zhao, Minjun Gao, Zongyun Chen, Yingliang Wu, Wenxin Li, Zhijian Cao

Journal:JOURNAL OF BIOLOGICAL CHEMISTRY

IF:4.01

DOI:10.1074/jbc.RA118.005015

PMID:30404919

Published:2018-11-07

research field:分子生物学药理学病毒学

Abstract

Viral infections still threaten human health all over the world, and many people die from viral diseases every year. However, there are no effective vaccines or drugs for preventing or managing most viral diseases. Thus, the discovery and development of broad-spectrum antiviral agents remain urgent. Here, we expressed and purified a venom peptide, Ev37, from the scorpion Euscorpiops validus in a prokaryotic system. We found that rEv37 can inhibit dengue virus type 2 (DENV-2), hepatitis C virus (HCV), Zika virus (ZIKV), and herpes simplex virus type 1 (HSV-1) infections in a dose-dependent manner at noncytotoxic concentrations, but that it has no effect on Sendai virus (SeV) and adenovirus (AdV) infections in vitro. Furthermore, rEv37 alkalized acidic organelles to prevent low pH–dependent fusion of the viral membrane–endosomal membrane, which mainly blocks the release of the viral genome from the endosome to the cytoplasm and then restricts viral late entry. Taken together, our results indicate that the scorpion venom peptide Ev37 is a broad-spectrum antiviral agent with a specific molecular mechanism against viruses undergoing low pH–dependent fusion activation during entry into host cells. We conclude that Ev37 is a potential candidate for development as an antiviral drug.

本文使用的Yeasen产品

购物车
客服
转染试用